A Goliath in the Making: The Unlikely Convergence of AstraZeneca and Bristol Myers Squibb The pharmaceutical industry is on the cusp of a seismic shift.
Britain's biggest drugmaker, AstraZeneca, is engaging in talks to merge with its US rival, Bristol Myers Squibb.
The proposed deal would create a behemoth worth nearly $400 billion, eclipsing even the most audacious predictions about the future of the sector. At first glance, the pairing seems unlikely.